Septerna (SEPN) Competitors

CG Oncology (NASDAQ:CGON) and Septerna (NASDAQ:SEPN) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, valuation, dividends, risk, analyst recommendations and earnings.

Is CGON or SEPN more profitable?

Septerna has a net margin of -12,053.03% compared to CG Oncology's net margin of -15,945.17%. CG Oncology's return on equity of -19.37% beat Septerna's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CG Oncology	-15,945.17%	-19.37%	-18.72%
Septerna	-12,053.03%	-31.52%	-23.65%

Do insiders and institutionals hold more shares of CGON or SEPN?

26.6% of CG Oncology shares are owned by institutional investors. 7.4% of CG Oncology shares are owned by insiders. Comparatively, 4.3% of Septerna shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Do analysts prefer CGON or SEPN?

CG Oncology presently has a consensus target price of $55.27, indicating a potential upside of 105.32%. Septerna has a consensus target price of $26.75, indicating a potential upside of 123.10%. Given Septerna's higher possible upside, analysts plainly believe Septerna is more favorable than CG Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CG Oncology	0 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.08
Septerna	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80

Does the media refer more to CGON or SEPN?

In the previous week, Septerna had 17 more articles in the media than CG Oncology. MarketBeat recorded 25 mentions for Septerna and 8 mentions for CG Oncology. CG Oncology's average media sentiment score of 0.50 beat Septerna's score of 0.15 indicating that CG Oncology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CG Oncology	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Septerna	4 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Which has higher valuation & earnings, CGON or SEPN?

Septerna has lower revenue, but higher earnings than CG Oncology. CG Oncology is trading at a lower price-to-earnings ratio than Septerna, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CG Oncology	$1.14M	1,800.57	-$88.04M	-$1.77	-15.21
Septerna	$1.08M	494.92	-$71.80M	-$10.09	-1.19

Summary

CG Oncology beats Septerna on 11 of the 16 factors compared between the two stocks.